These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 7542804)

  • 21. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
    Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
    EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
    Mathez D; Schinazi RF; Liotta DC; Leibowitch J
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral drug resistance.
    Japour AJ
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
    Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J
    AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
    von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
    J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
    Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P
    AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
    Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P; Danner SA; Mulder J; Loveday C; Christopherson C
    J Infect Dis; 1995 Jun; 171(6):1411-9. PubMed ID: 7539472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
    Lacey SF; Larder BA
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1428-32. PubMed ID: 7522429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
    Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
    Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.